Cargando…

Advantages and Recent Developments of Autologous Cell Therapy for Parkinson’s Disease Patients

Parkinson’s Disease (PD) is a progressive degenerative disease characterized by tremor, bradykinesia, rigidity and postural instability. There are approximately 7–10 million PD patients worldwide. Currently, there are no biomarkers available or pharmaceuticals that can halt the dopaminergic neuron d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osborn, Teresia M., Hallett, Penelope J., Schumacher, James M., Isacson, Ole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147334/ https://www.ncbi.nlm.nih.gov/pubmed/32317934 http://dx.doi.org/10.3389/fncel.2020.00058

Ejemplares similares

Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease
por: Hallett, Penelope J., et al.
Publicado: (2019)

A Nurr1 Agonist Causes Neuroprotection in a Parkinson’s Disease Lesion Model Primed with the Toll-Like Receptor 3 dsRNA Inflammatory Stimulant Poly(I:C)
por: Smith, Gaynor A., et al.
Publicado: (2015)

Progressive decline of glucocerebrosidase in aging and Parkinson's disease
por: Rocha, Emily M, et al.
Publicado: (2015)

Cell type-specific lipid storage changes in Parkinson’s disease patient brains are recapitulated by experimental glycolipid disturbance
por: Brekk, Oeystein Roed, et al.
Publicado: (2020)

Fibroblasts from idiopathic Parkinson’s disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2
por: Thomas, Ria, et al.
Publicado: (2021)

Neurite Collapse and Altered ER Ca(2+) Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation
por: Korecka, Joanna A., et al.
Publicado: (2018)

Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition
por: Smith, G. A., et al.
Publicado: (2015)

Comprehensive Cell Surface Antigen Analysis Identifies Transferrin Receptor Protein‐1 (CD71) as a Negative Selection Marker for Human Neuronal Cells
por: Menon, Vishal, et al.
Publicado: (2019)

Novel Results and Concepts Emerging From Lipid Cell Biology Relevant to Degenerative Brain Aging and Disease
por: Isacson, Ole, et al.
Publicado: (2019)

Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease
por: Wallom, Kerri-Lee, et al.
Publicado: (2021)

Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson’s disease
por: Kumar, Manoj, et al.
Publicado: (2023)

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
por: Huebecker, Mylene, et al.
Publicado: (2019)

Correction to: Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
por: Huebecker, Mylene, et al.
Publicado: (2020)

The advantages of artificial intelligence-based gait assessment in detecting, predicting, and managing Parkinson’s disease
por: Wu, Peng, et al.
Publicado: (2023)

Recent Advances in Biomarkers for Parkinson’s Disease
por: He, Runcheng, et al.
Publicado: (2018)

Sequence Effect in Parkinson’s Disease Is Related to Motor Energetic Cost
por: Tinaz, Sule, et al.
Publicado: (2016)

Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age
por: Brekk, Oeystein R., et al.
Publicado: (2018)

Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
por: Duffy, Megan F., et al.
Publicado: (2018)

Ceramides in Parkinson’s Disease: From Recent Evidence to New Hypotheses
por: Plotegher, Nicoletta, et al.
Publicado: (2019)

Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease
por: Davies, Sian E., et al.
Publicado: (2014)

Parkinson’s Disease Motor Subtypes Show Different Responses to Long-Term Subthalamic Nucleus Stimulation
por: Xu, Cuiping, et al.
Publicado: (2018)

Recent Developments in Parkinson's Disease
por: Tsai, Diane C.
Publicado: (1986)

Differences in subthalamic oscillatory activity in the two hemispheres associated with severity of Parkinson’s disease
por: Zhao, Xuemin, et al.
Publicado: (2023)

Effectiveness of Integrative Therapy for Parkinson’s Disease Management
por: Woo, Yeonju, et al.
Publicado: (2019)

Advantages, Pitfalls, and Developments of All Optical Interrogation Strategies of Microcircuits in vivo
por: Papaioannou, Stylianos, et al.
Publicado: (2022)

Loss of Lipid Carrier ApoE Exacerbates Brain Glial and Inflammatory Responses after Lysosomal GBA1 Inhibition
por: Connolly, Kyle J., et al.
Publicado: (2023)

Art therapy as a comprehensive complementary treatment for Parkinson’s disease
por: Ettinger, Tom, et al.
Publicado: (2023)

Advantages in functional imaging of the brain
por: Mier, Walter, et al.
Publicado: (2015)

Music Therapy Interventions in Parkinson’s Disease: The State-of-the-Art
por: Raglio, Alfredo
Publicado: (2015)

Current Experimental Studies of Gene Therapy in Parkinson's Disease
por: Lin, Jing-ya, et al.
Publicado: (2017)

Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
por: Fields, Carroll Rutherford, et al.
Publicado: (2019)

Recent developments in biomarkers in Parkinson disease
por: Schapira, Anthony H.V.
Publicado: (2013)

Recent developments in the treatment of Parkinson's Disease
por: Stoker, Thomas B, et al.
Publicado: (2020)

Accuracy of Step Count Estimations in Parkinson’s Disease Can Be Predicted Using Ambulatory Monitoring
por: Shokouhi, Navid, et al.
Publicado: (2022)

Gene Therapy: A Promising Approach for Neuroprotection in Parkinson’s Disease?
por: Valdés, Pamela, et al.
Publicado: (2016)

Glutamic Acid Transporters: Targets for Neuroprotective Therapies in Parkinson’s Disease
por: Li, Xiang, et al.
Publicado: (2021)

Mitochondrial Dysfunction in Parkinson’s Disease: From Mechanistic Insights to Therapy
por: Gao, Xiao-Yan, et al.
Publicado: (2022)

Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease
por: Su, Ruichen, et al.
Publicado: (2021)

Neural responses to advantageous and disadvantageous inequity
por: Fliessbach, Klaus, et al.
Publicado: (2012)

Recent Advances in Drug Therapy for Parkinson's Disease
por: Murakami, Hidetomo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e08pg7sk4pqk7g0b581rja4bk5